IMPT-601 is designed to overcome the suppressive tumor microenvironment by enhancing CAR T- cell infiltration, overcoming T-cell exhaustion, and reducing regulatory T-cell activity LOS ANGELES, Oct. 23, 2024 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company...
ImmPACT Bio to Present New Preclinical Data on Claudin18.2/TGF-β Bispecific CAR T-Cell Therapy IMPT-601 for Gastric Cancer at the SITC 39th Annual Meeting
Seaking AlphaSeeking Alpha / Seaking Alpha 17 hours ago 1 Views
Comments